Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 1
2022 1
2023 2
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
Malmberg R, Agema BC, Hofman MM, Oosterveld S, Bins S, Dumoulin DW, Joosse A, Aerts JGJV, Debets R, Koch BCP, van der Veldt AAM, van Leeuwen RWF, Mathijssen RHJ. Malmberg R, et al. Among authors: agema bc. Cancer Commun (Lond). 2025 Apr;45(4):471-475. doi: 10.1002/cac2.12661. Epub 2025 Jan 16. Cancer Commun (Lond). 2025. PMID: 39817458 Free PMC article. No abstract available.
Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study.
van Nijnatten RYM, Buijs SM, Agema BC, Fischer RMJ, Moghaddam-Helmantel IG, Contant CME, de Jongh FE, Huijben AMT, Kop M, van der Padt-Pruijsten A, Zuetenhorst HJM, van Schaik RHN, Koch BCP, Jager A, Koolen SLW, Mathijssen RHJ. van Nijnatten RYM, et al. Among authors: agema bc. Breast. 2025 Feb;79:103880. doi: 10.1016/j.breast.2025.103880. Epub 2025 Jan 9. Breast. 2025. PMID: 39813819 Free PMC article.
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Clin Pharmacol Ther. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. Clin Pharmacol Ther. 2024. PMID: 38494911
Improving the tolerability of osimertinib by identifying its toxic limit.
Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, Koch BCP, Dingemans AC, Mathijssen RHJ, Koolen SLW. Agema BC, et al. Ther Adv Med Oncol. 2022 Jun 3;14:17588359221103212. doi: 10.1177/17588359221103212. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677320 Free PMC article.
15 results